Table 1. Clinical characteristics of the healthy controls and the chronic hepatitis B (CHB) and acute-on-chronic liver failure (ACLF) patients.
| Healthy controls | CHB patients | ACLF patients | |
|---|---|---|---|
| N | 33 | 47 | 91 |
| Age (years) | 38 (20–58) | 35 (18–73) | 45.5 (16–77) |
| Gender (male:female) | 13:20 | 35:12 | 68:23 |
| ALT (U/L) | 18 (8–40) | 53.3 (8.7–1095.3) | 73.6 (12–1188) |
| AST (U/L) | 21.0 (18.0–28.0) | 49.8 (16.6–432.9) | 90.65 (8–1192) |
| TBIL (μmol/L) | 11.1 (4.0–16.0) | 19.1 (8.0–753.9) | 355.25 (13–965) |
| ALB (g/L) | 42.1 (40.5–45.3) | 38.2 (34.2–41.4) | 32.8 (19–47) |
| PALB (mg/L) | – | 117.4 (66.2–168.0) | 65.7 (26–212) |
| CHE (U/L) | – | 5845.0 (1539–13100) | 3996.5 (975–8930) |
| TBA (μmol/L) | – | 15.5 (1–276.3) | 161.7 (93.6–229.2) |
| CREA (μmol/L) | 62.0 (47.0–93.0) | 68.1 (1.32–95.7) | 65.1 (23–263) |
| BUN (mmol/L) | 4.84 (3.26–46.80) | 3.94 (2.03–40.40) | 5.11 (1–39) |
| PTA (%) | 95.5 (94–99.8) | 91.4 (9.27–116.2) | 35.3 (16.5–38.6) |
| INR | – | 0.99 (0.84–1.34) | 1.60 (1–4) |
| MELD | – | 4.98 (–5.49–35.30) | 20.5 (14.8–64.8) |
| Regucalcin (ng/mL) | 1.72 (1.44–2.39) | 3.76 (2.78–5.59) | 5.46 (4.32–6.58) |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; PALB: pre-albumin; CHE: cholinesterase; TBA: total bile acid; CREA: creatinine; BUN: blood urea nitrogen; PTA: prothrombin activity; INR: international normalized ratio; MELD: model for end-stage liver disease. Data are reported as medians (25–75th percentiles).